^
Association details:
| Biomarker: | PDGFRA mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/13/2023
Excerpt:
Gastrointestinal Stromal Tumor….Systemic Therapy Agents and Regimens for GIST...Preferred regimens: Imatinib for KIT or PDGFRA mutations (excluding PDGFRA exon 18 mutations that are insensitive to imatinib, including D842V).
Source:
Title:
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Excerpt:
...- Positive immunohistochemical staining for c-KIT (CD117); or negative staining for KIT, but with either positive staining for DOG1 or an identified mutation of KIT or PDGFRA gene...
Trial ID:
Source:
Title:
Jejunoileal vs Gastric GIST in the Era of Imatinib.
Excerpt:
...Number of patients with a molecular analysis positive for KIT mutation`KIT Gene mutation`Number of patients with a molecular analysis positive for PDGFRA mutation`PDGFRA Gene mutation`Number of patients with immunohistochemical expression of CD117`Expression of CD117`Number of patients with immunohistochemical expression of DOG1`Expression of DOG1`Number of patients with recurrence after treatment with tyrosinkin inhibitors.`...
Trial ID:
More C2 evidence
Source:
Title:
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Excerpt:
...To determinate the objective response rate (ORR, complete response + partial response) To determinate the time to tumor progression (TTP) To evaluate the safety and toxicity profiles of AUY922 To evaluate the pharmacokinetics profile of AUY922 in Taiwan GIST population To access the pharmacodynamic effect of AUY922 on HSP client proteins in blood and tumor if feasible , i.e. HSP70, in Taiwan GIST population To access the tissue biomarkers pre-treatment and 4wks post treatment if feasible, i.e. HSP70, c-KIT, PDGFRA mutation, ...etc in Taiwan GIST population...
Trial ID:
Source:
Title:
A study of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal tumors (GISTs) Estudio de Selinexor en combinación con imatinib en pacientes con tumores gastrointestinales (GISTs) metastasicos o irresecables
Excerpt:
...Exception to this rule is GIST patients with documented KIT or PDGFRA mutations.4. ...
Trial ID:
Source:
Title:
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
Excerpt:
...- Histologically confirmed gastrointestinal stromal tumor expressing CD117+ or with documented mutation of the KIT or PDGFRA gene...
Trial ID:
Source:
Title:
_
Excerpt:
...Histologically confirmed GIST of any anatomical location and confirmed by the RRePS Network ; positive immunohistochemical staining for c-KIT (CD117); or negative staining for KIT, but with either positive staining for DOG1 or an identified mutation of KIT or PDGFRA gene 3. ...
Trial ID:
Source:
Title:
Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment
Excerpt:
...Patients with demonstrated mutation in KIT or PDGFRA may be entered to the study despite negative immunostaining for KIT and DOG-1 provided that tumour histology is compatible with GIST. ...
Trial ID:
Source:
Title:
Imatinib TDM in GIST
Excerpt:
...- Histologically or cytologically confirmed GIST with KIT mutation or PDGFRA mutation (non-D842V)...
Trial ID:
Source:
Title:
SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST
Excerpt:
...Patients with demonstrated mutation in KIT or PDGFRA may be entered to the study despite negative immunostaining for KIT and DOG-1 provided that tumour histology is compatible with GIST....
Trial ID:
Source:
Title:
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
Excerpt:
...- Gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived growth factor receptor alpha (PDGFRA) exons 12 and 18...
Trial ID:
Source:
Title:
Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Excerpt:
...Histologically confirmed GIST of any anatomical location and confirmed by the RRePS Network ; positive immunohistochemical staining for c-KIT (CD117); or negative staining for KIT, but with either positive staining for DOG1 or an identified mutation of KIT or PDGFRA gene 3....
Trial ID:
Less C2 evidence
Source:
Title:
The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice
Published date:
08/16/2020
Excerpt:
The majority of GIST cases harboured exon 11 KIT mutations (88 cases, 82%), 11 cases had exon 9 KIT mutations (10%), 8 had other KIT/PDGFRA mutations potentially sensitive to imatinib. The disease relapse was detected in 19 patients, of them in 5 cases in exon 9 KIT mutants (45%), and 14 cases in patients with exon 11 KIT mutations (11%) [p < 0.01].
DOI:
10.1016/j.ejso.2020.08.004
Title:
Persistent Lymph Node Metastasis Post Imatinib Treatment in Low Grade Gastrointestinal Stromal Tumor with PDGFRA Mutation
Published date:
07/25/2020
Excerpt:
A 38-year-old male presented with a 11.5 cm epigastric GIST status... PDGFRA gene mutation detected by genetic analysis….The patient was managed with continuous imatinib treatment and life-long follow up.
DOI:
10.31487/j.AJSCR.2020.03.10
